Sean Pitroda, M.D.

Radiation oncologist & cancer biologist @UChicago @LudwigCancer investigating oligometastatic disease & interplay between radiotherapy & immunotherapy

[Sean Pitroda, M.D. @SeanPitroda]

1/ Our latest - @JAMAOncology Viewpoint! Ablative radiotherapy has a dual effect on metastatic cancer that changes how we should interpret progression after treatment.

[Sean Pitroda, M.D. @SeanPitroda]

@Jalal_Ahmed @NatureCancer Congrats!

[Sean Pitroda, M.D. @SeanPitroda]

@aadel_chaudhuri @Nature Congrats!

[Sean Pitroda, M.D. @SeanPitroda]

@piet_ost @LancetOncology @EORTC @ESTRO_RT @HendriksLizza @Mat_Guc @Icro_Meattini @FelixEhretMD @Hoda_Aty @Silke_Gillessen @finn_corinne @drdavidpalma Important @LancetOncology consensus endorses endpoints that permit repeat MDT without classifying it as failure - exactly what @rweichselbaum and I argued: radiation unmasks dormant disease, making standard progression a flawed benchmark.

https://t.co/2s8r6lffLW

[Sean Pitroda, M.D. @SeanPitroda]

@DrewMoghanaki @rweichselbaum @piet_ost We are pleased to share PersonaCRC - the first clinically validated biomarker for oligometastatic CRC - is available to order: https://t.co/IBAFlTat6C

Based on prior work from our group:
https://t.co/p6L6OKLHcA
https://t.co/3g74FHMxuY
https://t.co/Lb8bfMQsur

[Sean Pitroda, M.D. @SeanPitroda]

@DrewMoghanaki @rweichselbaum @piet_ost We are pleased to share PersonaCRC - the first clinically validated biomarker for oligometastatic CRC - is available to order: https://t.co/IBAFlTat6C

Based on prior work from our group:
https://t.co/p6L6OKLHcA
https://t.co/3g74FHMxuY
https://t.co/Lb8bfMQsur

[Patrick Forde @FordePatrick]

Hot Topics in Lung Cancer Basic and Translational Research is coming up! Submit your abstract by april 15 and come and visit in (hopefully) sunny Dublin!
Speakers include Drew Pardoll, @FSkoulidis @DrJNaidoo @CottrellLab @SeanPitroda among a glittering line up! #lcsm

[Simon Lo @SimonLo21054188]

⁦@SeanPitroda⁩ speaking in the Radiotherapy Overcome Immunotherapy Resistance Session ⁦@the_RSS⁩ 2026

[Journal of Clinical Investigation @jclinicalinvest]

IFN signaling at the nexus of the radiotherapy response in malignant peripheral nerve sheath tumors: https://t.co/an90PV9wdD

Sean P. Pitroda @SeanPitroda, Ralph Weichselbaum @rweichselbaum & team @UChicago provide a Commentary on Iowis Zhu et al.: https://t.co/e5hJOOyM4W

[Sean Pitroda, M.D. @SeanPitroda]

@rweichselbaum @UCCancerCenter @LudwigCancer Shocking indeed!

[Sean Pitroda, M.D. @SeanPitroda]

@max_diehn @CELL Congrats!

[JAMA Oncology @JAMAOnc]

💬 Viewpoint: The badscopal effect following ablative radiotherapy signals not failure but biological reorganization, prompting serial metastasis-directed therapy in selected patients. https://t.co/aNk5EQpv4i

[Open Medicine Insights @OpenMedInsights]

Radiotherapy duality in metastatic disease: inhibiting seeding, unmasking dormancy
Viewpoint | https://t.co/sgWagTKH7K
@SeanPitroda @rweichselbaum @JAMAOnc @JAMANetwork
Key insights
🟢 Metastasis-directed radiotherapy (MDT) suppresses metastatic seeding from treated lesions
🟢 Ablative RT can unmask dormant distant disease (“badscopal effect”) rather than promote spread
🟢 Post-MDT progression reflects biological reorganization, not treatment failure
🟢 Radiation reshapes systemic immunity (amphiregulin-mediated), enabling dormant clone outgrowth
🟢 Metastatic disease should be viewed as dynamic and iterable, not static

Clinical implications
🟢 Strong rationale for serial MDT, not one-time local therapy
🟢 Explains limited benefit in trials restricting MDT to a single round
🟢 Supports treat-all-visible-disease strategies when feasible
🟢 Calls for MDT personalization using immune phenotype, clonality, and metastatic kinetics
@seanmcbride @drjefstathiou

@SeanPitroda @rweichselbaum
@JAMAOnc @JAMANetwork
@seanmcbride @drjefstathiou

#Radiotherapy #OligometastaticDisease #Metastasis #CancerBiology #MDT #Oncology #JAMAOncology

[Sean Pitroda, M.D. @SeanPitroda]

@xrtGenomics @NatureCancer @nataliesilvermd @GeneCollector Congrats!

[Sean Pitroda, M.D. @SeanPitroda]

@ebludmir @ChadTangMD @drdavidpalma @CJTsaiMDPhD Agree - Important to develop additional data in this clinical context to move treatment paradigms forward and test these preclinical predictions.

[Sean Pitroda, M.D. @SeanPitroda]

1/ Our latest - @JAMAOncology Viewpoint! Ablative radiotherapy has a dual effect on metastatic cancer that changes how we should interpret progression after treatment.

[Sean Pitroda, M.D. @SeanPitroda]

@ChadTangMD @ebludmir @drdavidpalma @CJTsaiMDPhD Certain systemic therapies when given with RT might also obviate the need to irradiate all sites

[Sean Pitroda, M.D. @SeanPitroda]

@ChadTangMD @ebludmir @drdavidpalma @CJTsaiMDPhD Probably better to irradiate all sites and not leave untreated disease.

[Sean Pitroda, M.D. @SeanPitroda]

@ChadTangMD @ebludmir @drdavidpalma @CJTsaiMDPhD Thanks Chad. Sorry I don't understand. Can you clarify?

[Sean McBride @seanmmcbride]

I think Sean's thinking here has been clear from the get go. There's no claim of accelerated progression of non-irradiated mets in the SBRT arm compared to the non-SBRT arm.

The claim is simply that one biological driver of out-of-field progression, when it occurs post-SBRT, acknowledging it occurs LESS FREQUENTLY in the SBRT arms of the trials mentioned, may be amphiregulin driven immune suppression. His work has identified a druggable target that may make the SBRT arms of oligomet trials even more successful than they've already been. Kudos to him! #radonc

[Sean Pitroda, M.D. @SeanPitroda]

@CJTsaiMDPhD @drdavidpalma @NiuSanford @piet_ost @rweichselbaum We don't know the source of post-RT mets. Easy to assume pre-existing lesions destined to grow, but may be more complex. RT controls treated lesions and reduces seeding, yet progression occurs. Why not study mechanisms rather than assume we understand them?

[Sean Pitroda, M.D. @SeanPitroda]

@DrewMoghanaki @5_utr @drdavidpalma @NiuSanford @piet_ost @CJTsaiMDPhD @rweichselbaum @sueyom @NehaVapiwala @IyengarPuneeth Agree—no data show radiation increases metastatic rate. That's not our claim. It's the NATURE of post-RT metastases that remains unclear (dormancy reactivation vs. pre-destined growth) and requires investigation. Understanding mechanism matters for therapeutic strategy.